Hansoh Pharmaceutical Group CoHNSPF 90 ROA % is 13.03% as of Dec. 2025, which is 11% below its 10-year median of 14.56. GuruFocus rates HNSPF with a GF Score™ of 90/100 and a GF Value™ of $3.00 (Modestly Overvalued). Among 1,005 Drug Manufacturers companies, Hansoh Pharmaceutical Group Co ranks better than 92.94% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Hansoh Pharmaceutical Group Co's annualizedNet Income for the quarter that ended in Dec. 2025 was $687 Mil.
Hansoh Pharmaceutical Group Co's average Total Assets over the quarter that ended in Dec. 2025 was $5,275 Mil. Therefore, Hansoh Pharmaceutical Group Co's annualized ROA % for the quarter that ended in Dec. 2025 was 13.03%.
The historical rank and industry rank for Hansoh Pharmaceutical Group Co's ROA % or its related term are showing as below:
HNSPF'
s ROA % Range Over the Past 10 Years
Min: 8.64 Med: 14.56 Max: 30.62
Current: 15.75
During the past 10 years, Hansoh Pharmaceutical Group Co's highest ROA % was 30.62%. The lowest was 8.64%. And the median was 14.56%.
HNSPF's ROA % is ranked better than 92.94% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 2.72
vs HNSPF: 15.75
Hansoh Pharmaceutical Group Co (OTCPK:HNSPF) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Hansoh Pharmaceutical Group Co ROA % Related Terms
Hansoh Pharmaceutical Group Co ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansoh Pharmaceutical Group Co ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's ROA % distribution charts can be found below:
* The bar in red indicates where Hansoh Pharmaceutical Group Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Hansoh Pharmaceutical Group Co (HNSPF) has a ROA % of 13.03% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Hansoh Pharmaceutical Group Co and its competitors. This is 11% below median its historical median of 14.56. Over the past decade, Hansoh Pharmaceutical Group Co's ROA % has ranged from 8.64 to 30.62. According to the industry distribution chart, Hansoh Pharmaceutical Group Co ranks #71 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 7.1%.
Is Hansoh Pharmaceutical Group Co's ROA % too high?
Hansoh Pharmaceutical Group Co's current ROA % of 13.03% is 11% below median its 10-year median of 14.56. Over the past 10 years, this metric has ranged from a low of 8.64 to a high of 30.62. The Drug Manufacturers industry median ROA % is 2.72. Hansoh Pharmaceutical Group Co's value of 13.03% is 379% above this industry median. Based on the distribution chart, Hansoh Pharmaceutical Group Co ranks #71 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hansoh Pharmaceutical Group Co ranks #71 out of 1005 companies for ROA %. This places Hansoh Pharmaceutical Group Co in the top 7% of its industry — outperforming the majority of peers. The industry median ROA % is 2.72. Hansoh Pharmaceutical Group Co's value of 13.03% is 379% above this benchmark. Historically, Hansoh Pharmaceutical Group Co's own ROA % has ranged from 8.64 to 30.62 over the past decade. While the company's 10-year median is 14.56 vs. the industry median of 2.72, Hansoh Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.72, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansoh Pharmaceutical Group Co's current ROA % of 13.03% is 379% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Hansoh Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansoh Pharmaceutical Group Co's current ROA % is 13.03%, which is 11% below median its own 10-year median of 14.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.00, compared to a current price of $3.83 — trading 27.5% above its estimated fair value. The current ROA % is 13.03%, which is 11% below median its 10-year median of 14.56 and 379% above the Drug Manufacturers industry median of 2.72. Hansoh Pharmaceutical Group Co's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current ROA % is 13.03% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of $3.83 is trading 27.5% above its estimated GF Value™ of $3.00.
GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for HNSPF:
ROA %: 13.03% (11% below median its 10-year median of 14.56)
GF Value™: $3.00 vs. price of $3.83 (27.5% above fair value)
Industry Position: 379% above the Drug Manufacturers median (#71 of 1005)
No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansoh Pharmaceutical Group Co Business Description
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
90GF Score
Get the complete analysis for HNSPF
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HNSPF has been successfully added to your 
